• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio

    Frontage Bolsters Clinical Services Capabilities

    Sanofi Unveils EUROAPI as Name of New European API Company

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Sanofi Unveils EUROAPI as Name of New European API Company

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza

    Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center

    LSNE Expands Fill Finish and Lyophilization Ops
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe

    Schreiner MediPharm Joins DoseID Consortium
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Virtual Clinical Trials: The Future of Dermatology Studies

    Frontage Bolsters Clinical Services Capabilities

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    CDMO Cognate BioServices Teams Up with L7 Informatics

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    The Wasdell Group Earns ISO 13485 Certification
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Adare Pharma Solutions

    Syngene

    Flow Sciences

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Adare Pharma Solutions

    Emergent BioSolutions

    Syngene

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    How to Survive and Thrive During CDMO Climate Change

    Waking up to find all the CDMOs I’d known have been acquired.

    How to Survive and Thrive During CDMO Climate Change
    Related CONTENT
    • 20 Year Retrospective
    • Overcoming the Small Molecule Bioavailability Challenge
    • Deriving Value from Integrated cGMP and Pre-GMP Manufacturing Operations
    • Flamma Arrives in the U.S.
    • Contract Pharma’s 20th Anniversary Retrospective
    Paul Woitach, Managing Partner, Pharmaceutical Advisors LLC10.15.19
    Remember 20 years ago, when Contract Pharma was just starting, and issues were being etched onto stone tablets? Back then many companies were starting to see the growth in need for resources for outsourcing of development chemistry as an opportunity for better margins than fine chemicals, without pharmaceutical risk. Even paint companies tried to add API capacity. There was M&A activity, then demand contracted. Unfortunately, many sponsors suffered, having to quickly find new CDMOs when capacity was mothballed across the industry. A lot has changed! 

    Because we are all involved in picking possibly long-term relationships, the reasons behind the changes and the implications for selecting and managing CDMOs is, for me, more than an academic exercise. Possibly fundamental structural changes on both sides of the desk have both short-term and long-term implications for how we approach outsourcing. Larger sponsors are changing how they approach internal R&D, as well as in and out licensing. Smaller companies as a group are now taking on more of the early development risk. The acquirer is sometimes allowing the acquired to continue management of the  programs. Creative structuring of start-ups is both allowing the bigger companies to acquire specific assets rather than entire companies and is also helping to create small company development engines. These are just some of the factors that are quickly changing how we help people manage outsourcing.  

    We are seeing more activity in pursuit of orphan indications, 505b2s, fast track designations etc., putting pressure on the need for smaller scale commercial capability and later stage development capabilities earlier in relationships. Small companies formed around spun out assets and whole portfolios is changing how we’re approaching working with CDMOs. Also, in the mix is the increased importance of biologics and “alternative therapies” along with the impact that demand for capacity from generics has on CDMOs.

    As you know, many CDMOs started around specific capabilities—e.g. fast early development chemistry, SMB, SDD, high potency—and now there  are possibilities for increased availability of specialized capability. We see more complex, potent and more insoluble molecules possibly requiring complex delivery or smaller scale or all of the above and more. In the past, large sponsors seeded some technology at CDMOs, but large pharma have increased reliance on CDMOs for enabling technology where a CDMO with many projects can better develop and optimize technology than a single sponsor with infrequent utilization, and now we may have deep-pocket investors needing ways to differentiate. Cool.

    So, what do we do during a “perfect storm” of fundamental, disruptive structural changes and investor cash consolidating the people and facilities on which we depend?

    There are  potentially exciting examples of investing to bring together capabilities with potential to create speed and value within an umbrella of multiple sites. Unfortunately, there are also painful examples of investing to roll-up/buy books of business and consolidate operations with limited benefit to customers and where strong CDMO talent heads for the door. Very little is as it was a couple years ago, and the change is happening faster than ever. Let me allay fears, our practice is not for sale!

    So, what are we all to do? Navigating challenging waters calls for plotting a good course, knowing where the rocks are and being prepared for when the fog rolls in and obscures everything we see. I offer here some questions to ask yourself, some strategies to consider and some tips that will hopefully be useful. 

    If other industries are a guide, M&A activity may continue. Increasing multiples for CDMOs being acquired is great news for the sellers but we customers have to worry about more pressure on CDMOs to cut costs and find synergy and higher prices. Higher interest rates may increase these pressures. Many Chinese CDMOs are undertaking significant expansions and cross-continent M&A. As in the past, when there’s excess capacity, even the best CMOs can be hungry for business and be more aggressive on pricing. There are some approaches to business terms that can help mitigate some of the risk yet provide a win-win; but understanding the CDMOs financial situation and plans is more important than ever.

    So, what are the operational implications? Turn-around time from receipt of RFP to receipt of proposals that can be 3-6 weeks, has remained consistent with some, but has become much slower with others, requiring more effort by the sponsors. Where a CDMO has been acquired, some have needed more time to get technical input, develop the business and technical aspects of the proposal and obtain internal approvals. Some proposals are now being developed elsewhere, sometimes by a centralized corporate proposal group, sometimes located overseas. To manage through this is to do more homework in early screening to understand the CDMOs proposal process. Involving your CMC consultants earlier can help since they may have more experience and contacts within the “new” CDMO.
    As always, the process can take longer if your RFP is sparse, causing more CDMO questions and coordination within the CDMO to assemble the right technical team. You may also receive more of a general proposal with which you will have to either spend additional time refining or revising after you accept the proposal.

    Seen as ‘administrivia’ to some, it’s more important than ever to have a detailed RFP before you discuss specifics with CDMOs. It will also help avoid filling out project questionnaires from multiple CDMOs which can consume valuable scientist time and position you as a less sophisticated client that the CDMO expects to be more costly to serve and disruptive to their own timelines. 

    A detailed RFP does not have to be long. It does require that you really know your technical and business situation, requirements and deliverables and communicate them clearly to the CDMO. A strong technical package for the RFP will also enable a smoother kickoff. Often overlooked is clarity in the RFP on analytical requirements, leading to surprises on all sides and timeline changes. It pays to anticipate what the CDMO will need to generate a proposal and to assess whether you will be someone that will be easy for them to do business with. You are the customer but CDMOs don’t have unlimited ability to support every customer timeline and after all, we are not just buying material or binary data but registration-enabling information for us or for a future partner.

    With all the changes, it’s more important than ever to first generate a long list of possible CDMOs and then screen them to a manageable number to receive an RFP. So much has changed so quickly that assumptions and past experience may no longer be valid. It can also be more dangerous than ever to go forward solely on the recommendation of a colleague. A list of CDMO contacts is also a valuable asset that you can use again and again. Go to conferences like Contract Pharma, tap experienced consultants and colleagues in your network. Also try to understand the new entities’ corporate strategy and fit with how you would work with them as you create a long list. Are they investing in people, technology and facilities or are they simply consolidating? What’s the turnover looking like? Are good people leaving? Joining? What are other sponsors that are at similar stage and size as you experiencing? How busy is the CDMO? Can they support markets of interest and your future scale needs? If not, what are their plans? For example, if your plans include Japan, do they have experience with Japan, or will you have to spend to establish that capability together? While getting volume projections from clinical or commercial teams can sometimes be challenging, its often better to make assumptions they can react to than to wait for the “puff of white smoke.” Lastly, do you have a clear picture of your decision criteria and how you will know when it’s time to sign and what cost range to expect when you start the process?

    If a CDMO that you believe can be a fit has been acquired recently, expect that the new parent companies’ legal teams are probably not smaller, so more focus on the Ts & Cs early on matters more than ever with newly acquired companies. Of course, there’s always pressure to get started but the devil really is in the operational and business details of what is and isn’t included, so don’t wait too long with the finalists before proceeding with MSA discussions. If you have an MSA in place with a CDMO that is now part of another company, be prepared for the new CDMO to possibly want to update it—did you agree to the unilateral assignment clause in your last MSA? The devil is in the details. 

    We get many calls from companies that learned too late that the quality agreement did not include decision rights they expected or had terms that conflicted with the wording in the MSA, and now there is a disagreement. Experienced QA and operational review concurrent with MSA review can help prevent issues, especially with newly acquired sites aligning quality systems with new forms of MSAs coming from the Mothership. Whether working from your MSA or theirs—some CDMOs require theirs—working  from the CDMOs form of quality agreement helps avoid being an exception process for their operators. New corporate EHS may approach categorizing compounds differently than when you worked with the CDMO before, and you may find that they may not now take your program. The new parent may want your program at a “center of excellence” that they acquired, built or are building. This may be good or may be bad, but this also may lead to more interactions to get things done, until the new company hopefully reaches a more settled down state.

    CDMOs appear to be trying hard to put in place the new BD structure and processes that can support the new business models but be prepared for some to be bumpy. You may have a new BD contact or one you’ve worked with in the past that was excellent but may need more time to get answers on new capabilities. Bottom line, it’s prudent that you plan for more time for selection. Indeed, it can take time for initial CDAs as it is, and it typically takes longer with the larger companies that may want their form or return significant mark-ups on your form.   

    How do you make sure you get the A team in these new waters? Are the excellent people from the last project still there? Has there been attrition? Are the founders who were essential before still involved and do they have clout? Is the acquirer HQ more hands off or more involved? Is that a good thing or not? Has something changed that might make bigger sponsors now get the A team instead of you? 

    Regardless, sponsors of successful programs typically budget for the right level of coordination FTEs for ID, selection and oversight. CDMOs may mean well but a decision that they might make in a vacuum, may not be the best one for you. Often when there’s a problem, responsibility is closer to 51% to 49%  than mostly one side or the other.

    Sunshine peaking through the clouds?
    While there may be some hassles and pain as the industry goes through consolidation, glimmering through the clouds are some exciting potential upsides. Hopefully we will see broader and easier availability of some technologies. We are already seeing initiative to pursue increased availability of harder to find capabilities like beta lactams and hormones, containment/high potency of all scales and stages, more CDMOs offering pre-formulation/characterization, royalty-free capability in improving solubility, particle size and work with difficult APIs, flow chemistry, mAb platforms, serialization, etc. Hopefully all this will also finally enable greater ability for same-same comparisons across CDMOs as the breadth of capabilities under one roof will become more homogenous across CDMOs.

    Calm after the storm?
    The potential for the new landscape of CDMOs to enable better development options is exciting. But bigger does not work for everyone and the market is already reflecting that. Not all the good CDMOs are being acquired and some of the smaller CDMOs are still go-to places for certain capabilities. Some are investing and some are combining. Already some of the people that did not stay on as they were acquired are joining or starting smaller CDMOs. Some founders who sold are starting another of the same thing. Some good CDMOs in China and India continue to expand and improve, adding western footprints at the back-end of the process, adding a potentially valuable benefit for sponsors.
     
    For smaller sponsors to capitalize on the opportunity and manage the challenges calls for some new tools and approaches, and it calls for knowing more than ever what you need and how to buy it.
    Having been in calm waters for quite a while, where we knew the landmarks, we’ve now been blown out into the big water. For those who stock their ship appropriately and who are prepared to navigate with the right tools, new and promising destinations may be possible. But it will take hard work and the right crew to get there. 


    Paul Woitach is Managing Partner of Pharmaceutical Advisors LLC, a firm that helps clients plan and manage outsourced R&D while managing infrastructure. Paul helped found the practice in 2001 within Solutia and he was part of the group that acquired the practice from Solutia in 2005. Prior to Solutia, he led a turnaround and sale of divisions as CEO of Immunogenetics (IGI). Before that, he was North American General Manager for scientific instrument leader Mettler Toledo and was a Vice President with Kodak’s $2B Health Imaging Division. Mr. Woitach has served on the Board of Directors of public companies and on the Advisory Board of the Hackensack University Medical Center Life Sciences Institute. He is currently serving on the Board of Directors of the Camille and Henry Dreyfus Foundation, the Montgomery Township Board of Adjustment, and on the Advisory Board of the New Jersey Economic Development Authority Bioscience Center. Mr. Woitach holds an MBA from the William E. Simon School of Business.
    Related Searches
    • Pre-Formulation
    • fine chemicals
    • it
    • capacity
    Suggested For You
    20 Year Retrospective 20 Year Retrospective
    Overcoming the Small Molecule Bioavailability Challenge Overcoming the Small Molecule Bioavailability Challenge
    Deriving Value from Integrated cGMP and Pre-GMP Manufacturing Operations Deriving Value from Integrated cGMP and Pre-GMP Manufacturing Operations
    Flamma Arrives in the U.S. Flamma Arrives in the U.S.
    Contract Pharma’s 20th Anniversary Retrospective Contract Pharma’s 20th Anniversary Retrospective
    Designing a Successful Oligonucleotide Facility  Designing a Successful Oligonucleotide Facility
    Prince Sterilization Services Celebrates Three Generations of Microbiologists Prince Sterilization Services Celebrates Three Generations of Microbiologists
    The Bioprocessing Trek The Bioprocessing Trek
    Quality Metrics Feedback Quality Metrics Feedback
    Handling & Assessing HPAPIs Handling & Assessing HPAPIs
    Changing the Face of CDMOs Changing the Face of CDMOs
    Drug Substances: Scale-Up Challenges Drug Substances: Scale-Up Challenges
    API to ADC: A Journey Through High Potency API to ADC: A Journey Through High Potency
    Preparing for Your CDMO Selection Process Preparing for Your CDMO Selection Process
    iBio Announces 3D Bioprinting Agreement iBio Announces 3D Bioprinting Agreement

    Related Features

    • Excipients
      Bye-Bye China?

      Bye-Bye China?

      Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.
      Michele Jermini and Enrico Polastro 11.17.20

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20


    • The Single-Use Mixing Landscape: Evaluating Your Options

      The Single-Use Mixing Landscape: Evaluating Your Options

      Adoption of single-use technologies has increased markedly in recent years and will continue to grow.
      Mark A. Sitcoske, Founder & CEO, High Purity New England 11.17.20

    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      Lonza’s Director of Commercial Development, Sean Diver, was recently named President of DCAT.
      Tim Wright, Editor, Contract Pharma 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Injectables
      Catering for the Complex

      Catering for the Complex

      The rapidly changing landscape of pharmaceutical packaging.
      Marcelo Cruz, Director Business Development and Marketing, Tjoapack 11.17.20

    • Cold Chain Management | Supply Chain
      Cold Chain Trends

      Cold Chain Trends

      There is a growing need for convenience through Direct-to-Patient and Direct-from-Patient services in clinical trials.
      Vince Paolizzi, Director of NanoCool Sales, Pelican BioThermal 11.17.20

    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20


    • Scale-up/Technology Transfer
      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Defining the key parameters and considerations for a successful technology transfer.
      Tom Chang, President, Bora Pharmaceutical Laboratory Co. Ltd. 11.17.20

    • Scale-up/Technology Transfer
      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Identifying, assessing and mitigating threats at every stage of the development pipeline.
      Joe Willmot, Application Leader, H.E.L Group 11.17.20

    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20


    • APIs
      Understanding the Importance of Crystallization Processes

      Understanding the Importance of Crystallization Processes

      Crystallization is a crucial aspect of a molecule’s development and can be used to avoid unnecessary cost, risk and development delays.
      Dr. Craig Callahan, Project Scientist, Cambrex Edinburgh 10.14.20

    • Capsules | Solid Dosage/Creams/Ointments
      Capsule Technology Trends

      Capsule Technology Trends

      A look at the capsule market with a particular focus on the factors driving increased demand in non-gelatin-based formulations.
      Julien Lamps, Product Manager, Lonza 10.14.20

    • Aseptic Processing | Fill/Finish
      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      Overcoming today’s aseptic fill-and-finish process challenges.
      Ute Schleyer, Project Manager, Site & Plant Development, Vetter 10.14.20

    Trending
    • Fujifilm To Invest $2B In US Manufacturing Site
    • Baxter, Novavax Ink Sterile Manufacturing Agreement
    • A New Era Of Vaccine And Biologic Drug Development
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Roche Canada To Invest $500M To Create 500 Jobs In Ontario
    Breaking News
    • KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    • Frontage Bolsters Clinical Services Capabilities
    • Sanofi Unveils EUROAPI as Name of New European API Company
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Precision Medicine Group Acquires Project Farma
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Brown Fat Associated with Reductions in Chronic Disease Risk
    NIH Study Identifies Antibacterial Properties in Taurine
    NSF Begins New Certification Program
    Coatings World

    Latest Breaking News From Coatings World

    Zeppelin Acquires MTI Mischtechnik
    Ezio Braggio Joins ChemQuest Europe
    IFS Coatings Announce Carbon Offset Program
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Optimize EP Launches CaRM Cardiac Device Data Management Platform
    U.S. TAVR Market Projected to Reach Nearly $5 Billion by 2030
    FDA Clears Canon Medical's Compressed SPEEDER for 3D Exams on 1.5T MR
    Contract Pharma

    Latest Breaking News From Contract Pharma

    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    Frontage Bolsters Clinical Services Capabilities
    Sanofi Unveils EUROAPI as Name of New European API Company
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Neenah to Host Packaging Webinar for Printers
    W.S. Badger is Named a ‘150 Top Impact Company’
    Mana Products, Meiyume and RPG Form The Vertical Beauty Alliance
    Happi

    Latest Breaking News From Happi

    A Surge in Interest for Supplements & Vitamins
    What You're Reading on Happi.com
    Three Form Vertical Beauty Alliance
    Ink World

    Latest Breaking News From Ink World

    dar-tech, inc. Becomes U.S. Midwestern Distributor for ZS Interpolymer
    Techkon USA, Konica Minolta Partner
    Alon Bar-Shany Appointed Chairman of Highcon Board
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Exhibitor registration opens for virtual.drupa
    FTA planning in-person Forum & INFOFLEX
    Fortis Solutions Group achieves SGP certification
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Shemesh Adds U.S. Headquarters
    TZMO USA, Special Needs Group Form Partnership
    BAHP Announces 2021 Officers, Board of Directors
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Rapid Recovery Protocol Can Lead to Increased Range of Motion After TKA
    Boston Scientific Releases WaveWriter Alpha Spinal Cord Stimulators in U.S.
    New Chief Clinical Officer on Board at IncludeHealth
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Toppan Announces 2050 Environmental Vision
    SOI Industry Consortium Joins SEMI as Strategic Association Partner

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login